2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6232 Patients with cirrhosis complicated by blood loss anemia and sodium-glucose cotransporter-2 inhibitor exposure: A real-world cohort study

Jordan Nunnelee, MD, Yoshito Nishimura, M.D., PhD, MPH2, Richard C. Godby, MD3
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States

Introduction

Anemia is a common complication of hepatic cirrhosis, especially in the context of chronic variceal bleeding or other acute on chronic gastrointestinal bleeding as a result of portal hypertension. This acute on chronic anemia requires significant healthcare utilization, often including hospitalizations, ICU admissions, packed red blood cell (PRBC) transfusions, and/or parenteral iron infusions if iron deficient. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated pleiotropic anti-inflammatory, immunomodulatory, and other organ-protective effects beyond glycemic control. Moreover, SGLT2i increase endogenous erythropoietin (EPO) synthesis and hemoglobin levels without increased risk of myocardial infarction or venous thromboembolism. However, the potential impact of SGLT2i on survival, thrombosis rates, and anemia-specific factors in patients with cirrhosis complicated by anemia has not been elucidated.

Methods

We conducted a retrospective cohort analysis using an institutional de-identified data exploration tool, identifying adult patients diagnosed with cirrhosis with a diagnosis of anemia and esophageal varices or gastrointestinal bleed from March 2013 (first approval of SGLT2i) to February 2026. Patients were then stratified based on exposure to SGLT2i. The prespecified primary endpoint was hospitalization rate, and the secondary endpoint was five-year overall survival (OS). Propensity-score matching (PSM) was performed for the following covariates: age at diagnosis, race, ethnicity, sex, and diagnoses of type 2 diabetes mellitus, congestive heart failure, and chronic kidney disease. Mutually exclusive 1:1 matching was used with a caliper of 0.2. Survival was estimated by the Kaplan–Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox proportional-hazards models. Categorical outcomes were compared using the χ² test. A two-sided P value less than .05 was considered statistically significant.

Results

1,404 (10.3%) patients were exposed to SGLT2i and 12,189 (89.7%) were not exposed. There were 1,385 patients in each group after PSM. Baseline demographics in the PSM groups were comparable with a median age of 63.0 years (interquartile range (IQR) 59.0-69.0) at first diagnosis match. Patients in the SGLT2i exposed and unexposed groups were predominantly male (64.1% vs. 63.8%, P = .84).

SGLT2i exposure was associated with significantly fewer hospitalizations (30.2% vs. 35.5%, P < .001). Both two-year and five-year OS were significantly improved among patients exposed to SGLT2i compared to those not exposed (91.7% vs. 80.6%, HR 0.40, 95% CI: 0.32-0.50, P < .001; 83.1% vs. 60.0%, HR 0.37, 95% CI: 0.31-0.43, P < .001, respectively). SGLT2i exposure was associated with significantly fewer ICU admissions (11.3% vs.14.9%, P = .005). Patients exposed to SGLT2i had a significantly lower chance of receiving PRBC transfusion (10.5% vs. 12.9%, P = 0.044). There was no difference in parenteral iron replacement rate (6.9% vs. 5.8%, P = .24).

The rate of portal vein thrombosis was significantly lower in the SGLT2i exposed group (4.7% vs. 6.8%, P = .018). The percentage of patients diagnosed with hepatocellular carcinoma were similar among SGLT2i exposed and unexposed groups (6.6% vs. 5.8%, P = .39).

Conclusions

In this large real-world cohort of patients diagnosed with cirrhosis complicated by blood loss anemia, SGLT2i exposure was associated with reduced hospitalizations, improved short- and long-term OS, reduced ICU admissions, and lower PRBC exposure. There was lower rate of portal vein thrombosis, and a similar rate of hepatocellular carcinoma diagnosis. These findings suggest anemia-specific benefits of SGLT2i therapy that mitigate transfusion burden in these patients with acute on chronic blood loss anemia. While causality cannot be inferred from this retrospective analysis, further investigations and prospective evaluations are warranted to determine the potential benefits of SGLT2i therapy as an anemia-targeted adjunctive treatment in patients diagnosed with cirrhosis and who are at an increased risk of bleeding.

Jordan Nunnelee, MD: No relevant conflicts of interest to declare.